Low paraoxonase activity predicts coronary events in the Caerphilly Prospective Study

Circulation

Volumn 107, Issue 22, 2003, Pages 2775-2779

  Mackness, Bharti ^a   Durrington, Paul ^a   McElduff, Patrick ^b   Yarnell, John ^a   Azam, Naheed ^a   Watt, Michael ^a   Mackness, Michael ^a,c  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Antioxidants; Coronary disease; Lipoproteins; Myocardial infarction

Indexed keywords

ANTIOXIDANT; ARYLDIALKYLPHOSPHATASE; CLUSTERIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD SAMPLING; CHOLESTEROL TRANSPORT; COHORT ANALYSIS; CORONARY ARTERY DISEASE; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HEART INFARCTION; HUMAN; HYDROLYSIS; LIPID PEROXIDATION; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY;

AGED; ARYLDIALKYLPHOSPHATASE; CLUSTERIN; COHORT STUDIES; CORONARY DISEASE; ESTERASES; GLYCOPROTEINS; HUMANS; LIKELIHOOD FUNCTIONS; MALE; MIDDLE AGED; MOLECULAR CHAPERONES; ODDS RATIO; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TRIGLYCERIDES;

EID: 0038120009     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000070954.00271.13     Document Type: Article

References (38)

1. La Du BN. Human serum paraoxonase/arylesterase. In: Kalow W, ed. Pharmacogenetics of Drug Metabolism. New York: Pergamon Press; 1992:51-91.
2. Mackness B, Durrington PN, Mackness MI. Human serum paraoxonase. Gen Pharmacol. 1998;31:329-336.
3. Miller GJ, Miller NE. Plasma high-density lipoprotein concentration and the development of ischaemic heart disease. Lancet. 1975;i:16-19.
4. Parthasarathy S, Barnett J, Fong LG. High-density lipoprotein inhibits the oxidative modification of low-density lipoprotein. Biochim Biophys Acta. 1990;1044:275-283.
5. 2+-catalysed oxidation of human low-density lipoprotein. FEBS Lett. 1989;257:435-438.
6. Mackness MI, Abbott CA, Arrol S, et al. The role of high density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation. Biochem J. 1993;294:829-835.
7. Steinberg D, Parthasarathy S, Carew TE, et al. Beyond cholesterol modifications of low-density lipoprotein that increase its atherogenicity. N Engl J Med. 1989;320:915-924.
8. Mackness MI, Durrington PN. High density lipoprotein, its enzymes and its potential to influence lipid peroxidation. Atherosclerosis. 1995;115:243-253.
9. Mackness MI, Arrol S, Durrington PN. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. FEBS Lett. 1991;286:152-154.
10. Mackness MI, Arrol S, Abbott CA, et al. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. Atherosclerosis. 1993;104:129-135.
11. Watson AD, Berliner JA, Hama SY, et al. Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidised low-density lipoprotein. J Clin Invest. 1995;96:2882-2889.
12. Shih DM, Gu L, Xia Y-R, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394:284-287.
13. Aviram M, Billecke S, Sorenson R, et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulphydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase alloenzymes Q and R. Arterioscler Thromb Vasc Biol. 1998;10:1617-1624.
14. Aviram M, Hardak E, Vaya J, et al. Human serum paraoxonase (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation. 2000;101:2510-2517.
15. Adkins S, Gan KN, Mody M, et al. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet. 1993;52:598-608.
16. Humbert R, Adler DA, Disteche CM, et al. The molecular basis of the human serum paraoxonase activity polymorphism. Nature Genet. 1993;3:73-76.
17. Davies HG, Richter RJ, Keifer M, et al. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nature Genet. 1996;14:334-336.
18. Mackness MI, Arrol S, Mackness B, et al. The alloenzymes of paraoxonase determine the effectiveness of high-density lipoprotein in protecting low density lipoprotein against lipid-peroxidation. Lancet. 1997;349:851-852.
19. Mackness B, Mackness MI, Arrol S, et al. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett. 1998;423:57-60.
20. Mackness B, Mackness MI, Arrol S, et al. Effect of the molecular polymorphisms of human paraoxonase (PON1) on the rate of hydrolysis of paraoxon. Br J Pharmacol. 1997;112:265-268.
21. Durrington PN, Mackness B, Mackness MI. Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol. 2001;21:473-480.
22. Mackness B, Davies GK, Turkie W, et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol. 2001;21:1451-1457.
23. McElveen J, Mackness MI, Colley CM, et al. Distribution of paraoxon hydrolysing activity in the serum of patients after myocardial infarction. Clin Chem. 1986;32:671-673.
24. Navab M, Hama-Levy S, Van Lenten BJ, et al. Mildly oxidised LDL induces an increased apolipoprotein J/paraoxonase ratio. J Clin Invest. 1997;99:2005-2019.
25. Ayub A, Mackness MI, Arrol S, et al. Serum paraoxonase after myocardial infarction. Arterioscler Thromb Vasc Biol. 1999;19:330-335.
26. 55 genotype. Arterioscler Thromb Vasc Biol. 2000;20:2441-2447.
27. Jordan-Starck TC, Witte DP, Aronow BJ, et al. Apolipoprotein J: a membrane policeman? Curr Opin Lipidol. 1992;3:75-85.
28. Bainton D, Miller NE, Bolton CH, et al. Plasma triglyceride and high density lipoprotein cholesterol as predictors of ischaemic heart disease in British men: the Caerphilly and Speedwell Collaborative Heart Disease Studies. Br Heart J. 1992;68:60-66.
29. Rose GA. The diagnosis of ischaemic heart pain and intermittent claudicafion in field surveys. Bull World Health Org. 1962;27:645-658.
30. Blatter Garin M-C, Abbott C, Messmer S, et al. Quantification of human serum paraoxonase by enzyme-linked immunoassay: population differences in protein concentrations. Biochem J. 1994;304:549-554.
31. Sweetnam PM, Bolton CH, Downs LG, et al. Apolipoprotein A-I, A-II, and B, lipoprotein (a), and the risk of ischaemic heart disease: the Caerphilly Study. Eur J Clin Invest. 2000;30:947-956.
32. Wilson PWF, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
33. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico. Lancet. 1999;354:447-455.
34. Yusuf S, Degenais G, Pogue J, et al. Vitamin supplementation and cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:154-160.
35. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:23-33.
36. Boaz M, Smetana S, Weinstein T, et al. Secondary prevention with antioxidants of cardiovascular disease in end-stage renal disease (SPACE): randomised placebo-controlled trial. Lancet. 2000;356:1213-1218.
37. Durrington PN, Mackness B, Mackness MI. The hunt for nutritional and pharmacological modulators of paraoxonase. Arterioscler Thromb Vasc Biol. 2002;22:1248-1250.
38. Leviev I, Poirier O, Nicaud V, et al. High expressor paraoxonase PONI gene promoter polymorphisms are associated with reduced risk of vascular disease in younger coronary patients. Atherosclerosis. 2002;161:463-467.